Praxis Precision Medicines, Inc.

NasdaqGS PRAX

Praxis Precision Medicines, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2024: 15,168,557

Praxis Precision Medicines, Inc. Shares (Diluted, Weighted) is 15,168,557 for the Trailing 12 Months (TTM) ending September 30, 2024, a 197.39% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Praxis Precision Medicines, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2023 was 5,100,500, a 68.39% change year over year.
Praxis Precision Medicines, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2022 was 3,028,947, a 16.90% change year over year.
Praxis Precision Medicines, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2021 was 2,590,990, a 2,273.24% change year over year.
Praxis Precision Medicines, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2020 was 109,175.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqGS: PRAX

Praxis Precision Medicines, Inc.

CEO	Mr. Marcio Silva De'Souza M.B.A.
IPO Date	Oct. 16, 2020
Location	United States
Headquarters	99 High Street
Employees	82
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Key trends

Past 5 years